Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 114 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Vasomotor Symptoms Clear all

Conditions: Prostate Cancer Metastatic
Interventions: Veru-944, Placebo; Drug
Lead sponsor: Veru Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 24
States / cities: Glendale, Arizona • Los Angeles, California • San Bernardino, California + 20 more

Conditions: Vasomotor Symptoms Associated With Menopause, Hot Flashes
Interventions: Elinzanetant (BAY3427080), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 55
States / cities: Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 47 more

Conditions: Menopause
Interventions: Ashoka Bark and Shatavari, Placebo; Dietary Supplement · Other
Lead sponsor: Vidya USA Corporation; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Port Richey, Florida

Conditions: Hot Flashes, Stress
Interventions: Mindfulness-based stress reduction; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 40 Years to 69 Years · Female only
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Vasomotor Symptoms Associated With Menopause
Interventions: Black cohosh, Multibotanical preparation, Multibotanical preparation + dietary soy counseling, Conjugated equine estrogen +/- medroxyprogesterone acetate; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 45 Years to 55 Years · Female only
Enrollment: 351 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Depression, Menopause, Vasomotor Symptoms
Interventions: Duloxetine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Menopause, Menopause Related Conditions, Menopause Syndrome
Interventions: Hot water therapy, Warm water immersion; Behavioral
Lead sponsor: University of Colorado, Colorado Springs; Other
Eligibility: 40 Years to 80 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Colorado Springs, Colorado

Conditions: Vasomotor Symptoms
Interventions: Acupuncture; Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Winston-Salem, North Carolina

Conditions: Menopausal and Female Climacteric States
Interventions: Other: Placebo, GSK232802, PREMARIN; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 41
States / cities: Chandler, Arizona • Glendale, Arizona • Scottsdale, Arizona + 35 more

Conditions: Vasomotor Symptoms, Hot Flashes
Interventions: RAD1901, Placebo; Drug · Other
Lead sponsor: Radius Pharmaceuticals, Inc.; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Nasal Obstruction, Rhinitis, Vasomotor, Epistaxis
Interventions: Saline mixture; Other
Lead sponsor: Lisa Shnayder; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Prostate Cancer, Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Disease, Prostate Cancer Recurrent, Prostate Carcinoma, Prostate Neoplasm, Prostate Adenocarcinoma, Prostate Cancer With Bone Metastasis, Vasomotor Disturbance, Vasomotor Symptoms, Vasomotor Symptoms (VMS), Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Vasomotor Symptoms; Hot Flashes, Androgen Deprivation Therapy, Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma, Androgen-deprivation Therapy, Hot Flashes, Hot Flushes, Hot Flushes and/or Sweats
Interventions: fezolinetant - reference formulation, Placebo; Drug
Lead sponsor: Shehzad Basaria, M.D.; Other
Eligibility: 40 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hot Flashes
Interventions: Gabapentin Extended Release, Placebo; Drug
Lead sponsor: Depomed; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 66
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more

Conditions: Hot Flushes, Vasomotor Symptoms
Interventions: MF101 5 g/day, Placebo, MF101 10 g/day; Drug
Lead sponsor: Bionovo; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 50
States / cities: Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 44 more

Conditions: Menopause Hot Flashes
Interventions: MT-8554 1mg, MT-8554 5mg, MT-8554 10mg, Placebo; Drug
Lead sponsor: Tanabe Pharma America, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 63
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 50 more

Conditions: Menopause
Interventions: Placebo, S-equol; Drug
Lead sponsor: Ausio Pharmaceuticals, LLC; Industry
Eligibility: Female only
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: Louisville, Kentucky • Cincinnati, Ohio • Cleveland, Ohio + 2 more

Conditions: Postmenopausal Symptoms
Interventions: Brisdelle (paroxetine mesylate), Placebo capsules; Drug
Lead sponsor: Noven Therapeutics; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 74
States / cities: Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 63 more

Conditions: Vasomotor Symptoms
Interventions: DVS-233 SR; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: Female only
Enrollment: 540 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2004
U.S. locations: 41
States / cities: Montgomery, Alabama • Peoria, Arizona • San Diego, California + 36 more

Conditions: Hot Flashes
Interventions: Brisdelle (paroxetine mesylate), Placebo capsules; Drug
Lead sponsor: Noven Therapeutics; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 32
States / cities: Montgomery, Alabama • Chandler, Arizona • San Diego, California + 28 more

Conditions: Hot Flashes, Hot Flushes, Vasomotor Symptoms
Interventions: Stellate Ganglion Block Injection with Bupivicaine, Saline injection; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 40 Years to 70 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Menopause
Interventions: Placebo, S-equol; Dietary Supplement
Lead sponsor: Pharmavite LLC; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Breast Cancer, Hot Flashes, Sexual Dysfunction, Fertility, Contraception
Interventions: Reproductive Health Survivorship Care Plan (SCPR), Control; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Post-menopausal Vasomotor Symptoms
Interventions: ACER-801 50 mg BID, ACER-801 100 mg BID, ACER-801 200 mg BID, Placebo; Drug
Lead sponsor: Acer Therapeutics Inc.; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Hot Flushes, Menopause, Postmenopause
Interventions: Esterified Estrogens (EE) and Methyltestosterone (MT); Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 1,251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 88
States / cities: Montgomery, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 69 more

Search by objective public record fields.

Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause

Satavari and Ashoka for Menopause (SAM) Study

Mindfulness Based Stress Reduction for Hot Flashes

Herbal Alternatives for Menopause Symptoms (HALT Study)

Duloxetine for Menopausal Depression

Hot Water Therapy for the Treatment of Menopause-related Hot Flashes

Acupuncture in Menopause

Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)

Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms

Nasal Saline Irrigation After Radiation Therapy for Oropharyngeal Cancer

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women

A Study of MF101 in Postmenopausal Women

MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women

Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients

Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)

Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause

24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms

Stellate Ganglion Blockade in Post-Menopausal Women

A Nutritional Supplement on Vasomotor Symptoms in Women

Reproductive Health Survivorship Care Plan

Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause

Comparison of Estrogen and Methyltestosterone Combination Treatments for Postmenopausal Hot Flushes